Home > Insider Trading > Filing (0001209191-13-054043)

Filing Details

Accession Number:: 0001209191-13-054043
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-25 19:41:27
Reporting Period:: 2013-11-21

Filing Date:: 2013-11-25
Accepted Time:: 2013-11-25 19:41:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492426	Horizon Pharma Inc.	HZNP	Pharmaceutical Preparations (2834)	272179987

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1250409	W Jeffrey Bird	755 Page Mill Road, Suite A-200 Palo Alto CA 94304-1005		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-21	104,670	$6.24	2,201,228	No	4	P	Indirect	By Ltd. Partnership
Common Stock	Acquisiton	2013-11-21	46,419	$6.24	46,419	No	4	P	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Ltd. Partnership
No	4	P	Indirect	By Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Convertible Promissory Note	Acquisiton	2013-11-22	0	$5,093,000.00	949,477	$5.36

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2018-11-15	No	4	A	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,000	Direct
Common Stock	7,000	Indirect	By Ltd. Partnership
Common Stock	99,912	Indirect	By Trust

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.25, inclusive. The reporting person undertakes to provide Horizon Pharma, Inc., any security holder of Horizon Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding thenumber of shares purchased at each separate price within the range set forth in this footnote.
Securities held by Sutter Hill Ventures, A California Limited Partnership. The reporting person is a Managing Director of the General Partner of Sutter Hill Ventures, A California Limited Partnership. The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein.
Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.
Shares held by a limted partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.
The promissory notes will be convertible at the option of the holder on or after August 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date for the notes. Prior to the close of business on the business day immediately preceding August 15, 2018, the promissory notes will be convertible by the holder only under certainconditions, as set forth in the indenture governing the notes.